Guobang Pharma (SH:605507)2023-10-18 16:00Financial Performance - The diluted earnings per share for the third quarter is CNY 0.24, a decrease of 40.00% compared to the previous year[6]. - The net profit attributable to shareholders decreased by 41.78% in the third quarter, primarily due to the decline in prices of key products[8]. - The net profit attributable to shareholders for the year-to-date decreased by 32.17% compared to the previous year[8]. - Net profit attributable to shareholders of the listed company for the first three quarters of 2023 was RMB 489,073,265.39, down 41.78% from RMB 721,064,644.06 in the same period of 2022[17]. - Operating profit for the first three quarters of 2023 was RMB 563,975,837.46, down from RMB 840,332,164.25 in the same period of 2022, representing a decline of 32.9%[17]. - The total profit for the first three quarters of 2023 was RMB 559,550,561.80, down from RMB 830,436,121.65 in the same period of 2022, indicating a decline of 32.5%[17]. Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 9,779,405,912.97, representing an increase of 8.14% from the end of the previous year[6]. - Total assets as of September 30, 2023, amounted to CNY 9,779,405,912.97, an increase from CNY 9,043,184,958.17 in the previous year, reflecting a growth of approximately 8.14%[45]. - The total liabilities reached CNY 2,472,439,205.77, compared to CNY 1,888,579,890.48 in the previous year, indicating an increase of about 30.85%[45]. - The company’s total current liabilities increased to CNY 2,056,556,519.87 from CNY 1,862,382,165.88, reflecting a rise of about 10.43%[37]. - Non-current assets totaled CNY 4,649,796,249.35, up from CNY 3,913,865,466.88, indicating an increase of approximately 18.79%[36]. Cash Flow - The net cash flow from operating activities for the year-to-date decreased by 98.22%, primarily due to significant prepayments for raw material purchases[8]. - Cash flow from operating activities for the first three quarters of 2023 was RMB 10,895,807.14, a significant decrease of 98.22% compared to the previous year[24]. - The company reported a net cash outflow from financing activities of RMB -164,313,936.32 in the first three quarters of 2023, compared to a net inflow of RMB 472,113,835.59 in the same period of 2022[20]. - Operating cash inflows totaled approximately CNY 3.11 billion, an increase from CNY 2.90 billion year-over-year[49]. - Cash outflows from operating activities amounted to CNY 3.10 billion, compared to CNY 2.28 billion in the previous year[49]. - Net cash flow from operating activities was CNY 10.90 million, a significant decrease from CNY 611.76 million year-over-year[49]. - Cash received from tax refunds was CNY 233.90 million, an increase from CNY 177.13 million year-over-year[49]. Shareholder Information - The number of common shareholders at the end of the reporting period was 30,348, with the largest shareholder holding 23.08% of the shares[30]. Research and Development - Research and development expenses increased to RMB 162,761,109.22 in the first three quarters of 2023, compared to RMB 135,060,342.49 in the same period of 2022, reflecting a growth of 20.5%[16].